Document is current

Any future updates will be listed below

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2023-SITC2023.0651

Published Online: 2023-11-02

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark